Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole SodiumCategory 1.1 Ne...

HONG KONG, 17 July 2013 – Sihuan Pharmaceutical Holdings Group Ltd. announced that Anaprazole Sodium, a Category 1.1 new drug received the Approval for Clinical Studies from the State Food and Drug Administration (“SFDA”) of the People’s Republic...

Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole SodiumCategory 1.1 New Drug Clinical Studies
2014-12-23
Congrats to Beijing Sihuan on Receiving the Certificate of New Technology and New Product by Zhongguancun Science Park

On December 15, 2014, ZhongguancunScience Park announced the recipients of the Certificate of New Technology and New Product (Service), Beijing Sihuan Pharmaceutical Co., Ltd.was awarded the Certifica...

2014-12-23
Congrats to Beijing Sihuan on Winning Innovation Achievement Award of 2014 Product Quality Innovation and Contribution A

On December 18, 2014, Beijing ProductsEvaluation Center announced the recipients of the 2014 Product Quality Innovation and Contribution Award, Beijing SihuanPharmaceutical Co., Ltd. was granted with ...

2014-12-02
Congrats to Beijing Sihuan on Winning Product Excellence Award of “Science & Technology Innovation Award 2014”

On November 28, the “Science & Technology Innovation Award 2014” organized by Beijing Enterprise Evaluation Association was successfully concluded, Beijing Sihuan pharmaceutical co., Ltd.

2014-11-28
Xuanzhu Pharma Received the Formal Letter from U.S. FDA on Approval of Pirotinib to Start Clinical Trials

On November 27 (November 26, U.S. time), Xuanzhu Pharma Co., Ltd., a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings Group Ltd., received the formal letter from the U.S. FDA that formally approved the anti-tumor patented new drug Pirotinib (KBP5209) to enter into clinical trials.

2014-11-11
Sihuan Pharmaceutical Secures IND Number for Self-Developed Innovative Patented Oncology Drug ‘Pirotinib’

Sihuan Pharmaceutical Holdings Group Ltd. has submitted an Investigational New Drug (IND) application for Pirotinib (“Pirotinib” or the “new drug”), a self-developed innovative patented oncology d...

Total 8 Pages  First page  Page up  Page down  Last page

Select

  • 2015
  • 2014
  • 2013
  • 2012